The Filing Desk

ImmuCell vs Insight Molecular Diagnostics

ImmuCell ICCC · Insight Molecular Diagnostics IMDX · Health Care Supplies

ImmuCell reported revenue of $28 million in fiscal 2025, 6.7 times Insight Molecular Diagnostics' $4 million in fiscal 2025. ImmuCell's revenue grew 4.3% in its latest year, and Insight Molecular Diagnostics' grew 115.6%. ImmuCell had an operating margin of 6.0%, against -1260.8% at Insight Molecular Diagnostics. Free cash flow was $1 million at ImmuCell and −$25 million at Insight Molecular Diagnostics.

Side by side

ImmuCellInsight Molecular Diagnostics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$28M$4M
Revenue growth4.3%115.6%
Revenue growth a year, last 5 years12.5%27.9%
Gross margin41.4%56.7%
Operating margin6.0%−1,260.8%
Net margin−3.8%−1,238.5%
Free cash flow$1M−$25M
Free cash flow margin4.4%−625.6%
Return on capital——
Net debt to EBITDA1.2x—
Dividends and buybacks$0M$0M
Change in diluted share count10.5%133.2%
Last close$11.17$1.66
P/E at the last close58.8×—
Insider trades, last 12 monthsbought $140,146, sold $0bought $11.7 million, sold $0
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ImmuCellInsight Molecular Diagnostics
Operating margin
Percent of revenue
ImmuCellInsight Molecular Diagnostics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ImmuCellInsight Molecular Diagnostics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ImmuCell and Insight Molecular Diagnostics pages.